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Abstract 
Background: Uncertainty about the optimal respiratory support strategies in critically ill COVID‑19 patients is wide‑
spread. While the risks and benefits of noninvasive techniques versus early invasive mechanical ventilation (IMV) are 
intensely debated, actual evidence is lacking. We sought to assess the risks and benefits of different respiratory sup‑
port strategies, employed in intensive care units during the first months of the COVID‑19 pandemic on intubation and 
intensive care unit (ICU) mortality rates.
Methods: Subanalysis of a prospective, multinational registry of critically ill COVID‑19 patients. Patients were subclas‑
sified into standard oxygen therapy ≥10 L/min (SOT), high‑flow oxygen therapy (HFNC), noninvasive positive‑pressure 
Page 2 of 12Wendel Garcia et al. Crit Care          (2021) 25:175 
Keywords: COVID‑19, ARDS, Respiratory support, 
Noninvasive mechanical ventilation, High flow oxygen 
therapy, Invasive mechanical ventilation, Standard oxygen 
therapy, Patient self‑inflicted lung injury
Background
Coronavirus disease 2019 (COVID-19) has generated 
a surge of critically ill patients who require invasive 
mechanical ventilation (IMV) overburdening intensive 
care units (ICU) worldwide.
Traditionally, the treatment of acute respiratory dis-
tress syndrome (ARDS) has focused mainly on IMV and 
its optimization [1]; nonetheless, in the last decade new 
approaches have been increasingly explored, primar-
ily high-flow oxygen therapy by nasal cannula (HFNC) 
and noninvasive positive-pressure ventilation (NIV) [2, 
3]. At the onset of the COVID-19 pandemic, most clini-
cians supported by the recommendations of international 
guidelines employed either standard oxygen therapy 
(SOT) or early IMV for the treatment of COVID-19-in-
duced ARDS (CARDS) [4]. This choice was probably 
influenced by the numerous uncertainties regarding the 
new pathology, but also to avoid endangering hospi-
tal personnel by generating aerosols with HFNC and 
NIV. Nonetheless, in certain areas and centers, a lack of 
mechanical ventilators and adequately trained ICU staff 
forced clinicians to use noninvasive techniques to treat 
CARDS [5].
The high mortality rate associated with CARDS 
observed at the start to the pandemic has decreased 
over time [6, 7]. While many factors may explain this 
improvement, the decision to use invasive or nonin-
vasive respiratory support remains one of the most 
controversial ones [8]. Expert opinions range widely. 
While some eminent authors urge for early intuba-
tion at the first signs of respiratory fatigue, to prevent 
patient self-inflicted lung injury (P-SILI) [9–12], others 
argue that all noninvasive options should be exhausted 
before proceeding to IMV [13–18]. Nevertheless, there 
is a surprising lack of evidence regarding the optimal 
respiratory support strategy.
The present study was designed in the context of the 
ubiquitous uncertainty surrounding respiratory sup-
port strategies in critically ill COVID-19 patients. This 
study consists of a subanalysis of the data collected 
prospectively in the RISC-19-ICU registry [19]. The 
main objective was to determine which respiratory sup-
port strategy employed during the first months of the 
COVID-19 pandemic was associated with a better over-
all prognosis. To reflect the early intubation trend fol-
lowed during the first months of the pandemic, patients 
directly intubated on ICU admission but with matched 
severity characteristics to the noninvasively supported 
patients were also included in the analysis, constituting 
an independent respiratory support strategy.
Methods
This was a retrospective subanalysis of data from the pro-
spective RISC-19-ICU registry, which contains a stand-
ardized dataset of all critically ill COVID-19 patients 
admitted to the collaborating centers during the ongoing 
pandemic.
The RISC-19-ICU registry was deemed exempt from 
the need for additional ethics approval and patient 
informed consent by the ethics committee of the canton 
of Zurich (KEK 2020-00322, ClinicalTrials.gov Identi-
fier: NCT04357275). The present study complies with 
the tenets of the Declaration of Helsinki, the Guidelines 
on Good Clinical Practice (GCP-Directive) issued by the 
European Medicines Agency, as well as Swiss law and 
Swiss regulatory authority requirements. All collaborat-
ing centers have complied with all local legal and ethical 
ventilation (NIV), and early IMV, according to the respiratory support strategy employed at the day of admission to 
ICU. Propensity score matching was performed to ensure comparability between groups.
Results: Initially, 1421 patients were assessed for possible study inclusion. Of these, 351 patients (85 SOT, 87 HFNC, 87 
NIV, and 92 IMV) remained eligible for full analysis after propensity score matching. 55% of patients initially receiving 
noninvasive respiratory support required IMV. The intubation rate was lower in patients initially ventilated with HFNC 
and NIV compared to those who received SOT (SOT: 64%, HFNC: 52%, NIV: 49%, p = 0.025). Compared to the other 
respiratory support strategies, NIV was associated with a higher overall ICU mortality (SOT: 18%, HFNC: 20%, NIV: 37%, 
IMV: 25%, p = 0.016).
Conclusion: In this cohort of critically ill patients with COVID‑19, a trial of HFNC appeared to be the most balanced 
initial respiratory support strategy, given the reduced intubation rate and comparable ICU mortality rate. Nonetheless, 
considering the uncertainty and stress associated with the COVID‑19 pandemic, SOT and early IMV represented safe 
initial respiratory support strategies. The presented findings, in agreement with classic ARDS literature, suggest that 
NIV should be avoided whenever possible due to the elevated ICU mortality risk.
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requirements. As of October 1, 2020, 63 collaborating 
centers in 10 countries, were actively contributing to the 
RISC-19-ICU registry. For further specifications on the 
RISC-19-ICU registry structure and data collection, see 
Additional file 1: e-Appendix 1.
Inclusion and exclusion criteria
Patients were included in the present substudy if they 
required SOT (≥10 L/min [20]), HFNC, NIV, or IMV at 
the time point of admission to the ICU defined as day 0. 
Patients without a full ICU outcome data set, with SOT 
<10 L/min, or with a do-not-intubate order at day 0 were 
excluded. For the days ensuing ICU admission, the daily 
respiratory support therapy was defined as the main 
strategy used during the chart day.
Initial ventilation support group definitions
For study purposes, patients were categorized into four 
groups according to their maximal respiratory support 
at ICU admission (day 0), as follows: (1) SOT group: 
patients receiving SOT with an oxygen flow of ≥10 L/min 
 (FiO2 was approximated based on the delivered oxygen 
flow as described by Farias et al. [21]); (2) HFNC group: 
patients receiving HFNC, defined as a device delivering 
humidified and heated oxygen at a flow rate above 30 L/
min; (3) NIV group: patients receiving NIV, irrespective 
of interface, mode and ventilator type employed; and (4) 
IMV group: intubated patients receiving IMV.
Statistical analysis
Missing data handling is described in Additional 
file 1: e-Appendix 2. Comparisons of population charac-
teristics were performed using the analysis of variance or 
Kruskal–Wallis test, as appropriate, and the Chi-squared 
test for categorical variables. Nearest neighbor match-
ing with a propensity score caliper distance of 0.1 was 
employed to select IMV patients with ICU admission 
characteristics comparable to those of the patients in the 
SOT, HFNC and NIV groups. Patients having received 
IMV in another institutions ICU before admission to 
the RISC-19-ICU center were excluded from the match-
ing process. To enable comparability between IMV and 
the noninvasive respiratory support strategies, Sequen-
tial Organ Failure Assessment (SOFA) and Simplified 
Acute Physiology II (SAPS II) scores were used without 
the mechanical ventilation and neurologic sub-scores 
for the matching process. An optimal quality match was 
defined as a standardized mean difference (SMD) ≤0.1 
per matching variable between patients in the IMV group 
and the other groups (SOT, HFNC and NIV) [22].
Univariable Cox proportional hazard models coupled 
to the Kaplan–Meier estimator were employed to ana-
lyze the effects, represented by hazard ratios (HR), of the 
different respiratory support strategies on the incidence 
of intubation, ICU mortality and discharge from ICU. 
Multivariable adjusted HRs were calculated for every 
model independently by means of an iterative, step-wise, 
maximum likelihood optimizing algorithm, controlling 
for collinearity, interactions, and effect size variation in 
every iteration. The maximum number of covariates per 
model was chosen to ensure 1 to 10 events per covari-
ate. Comparison of survival distributions among the 
various respiratory support strategies was approached by 
means of the log-rank test. Proportional hazard assump-
tions were assessed through inspection of Schoenfeld 
residuals.
Generalized linear regression model (GLM) analy-
sis, considering all recorded baseline characteristics 
at ICU admission, was employed to determine the 
best predictive model for mortality in patients initially 
receiving HFNC and NIV and requiring delayed IMV. 
Multivariable GLM analysis was performed by means of 
an iterative, step-wise, maximum likelihood optimizing 
algorithm initially considering all variables with p<0.1 
on the univariable analysis. First-order interaction terms 
between the predictor variables were tested for all mod-
els, and excluded if not improving the final model fit. For 
the final GLM model, a prognostic score and nomogram 
were generated, and receiver operating characteristics 
(ROC) analysis was employed alongside minimal Euclid-
ean distance fitting to the (0, 1) point to determine the 
optimal cut-off value for the generated score. 95% con-
fidence intervals (CI) and p values comparing the prog-
nostic score to classic severity scores were generated by 
means of the bootstrap percentile method.
Statistical analysis was performed through a fully 
scripted data management pathway using the R environ-
ment for statistical computing version 3.6 .1. Due to the 
observational, prospective nature of this cohort study no 
power calculations were performed. A two-sided p <0.05 
was considered statistically significant. Values are given 
as medians with interquartile ranges (IQR) or counts and 
percentages as appropriate.
Results
Baseline and matching
Between March 13 and September 6, 2020, 1421 patients 
were included into the RISC-19-ICU registry. Of these 
877 met the inclusion criteria at ICU admission (Fig. 1). 
During the first 24 hours of ICU stay, 618 (70%) patients 
had been intubated and were receiving mechanical venti-
lation; of the remaining 259 patients, 85 (10%) were being 
treated with SOT, 87 (10%) with HFNC and 87 (10%) 
with NIV. Compared to the other three groups, patients 
under IMV presented higher severity scores, including 
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increased need for vasoactive medication (Additional 
file 1: e-Table 1).
To allow for an unbiased assessment of respiratory 
strategies, a comparable population of IMV patients was 
extracted by propensity score matching against the other 
three groups based on 22 clinical, severity and laboratory 
parameters at admission (Additional file  1: e-Figure  1). 
After the matching process, 351 patients (85 SOT, 87 
HFNC, 87 NIV and 92 IMV) were included in the final 
analysis. Matching quality was considered excellent, as 
reflected by an SMD ≤ 0.1 for all matching variables, 
excepting SAPS II (SMD = 0.13), bilirubin (SMD = 0.12), 
and mean arterial pressure (SMD =  0.11), in which the 
mean distributional difference between groups was none-
theless negligibly small (Additional file 1: e-Figure 1).
Characteristics of the overall population
After the matching process, the baseline characteris-
tics across all four groups at ICU admission were simi-
lar (Table  1, Additional file  1: e-Table  2). Patients were 
treated at 49 different ICUs, all of which followed dif-
ferent ventilation approaches. Until IMV was required 
or the patient could be weaned, no obvious crossovers 
between ventilation therapies seem to have been pre-
sent (Additional file 1: e-Table 3). Further, there was no 
obvious temporal relationship between the period of 
the pandemic during which patients were admitted to 
the ICU and the use of a specific respiratory support 
strategy or mortality rate (Additional file  1: e-Figure  2 
and e-Figure 3).
Of the patients who were not intubated and invasively 
ventilated on ICU admission, 55% required intubation 
and IMV between the first and second day of their ICU 
stay. A smaller proportion of patients (p = 0.025) in the 
HFNC (52%) and NIV (49%) groups progressed toward 
delayed IMV, compared to those in the SOT group (64%) 
(Fig. 2a).
Overall, the ICU mortality rate was higher (p = 0.016) 
in patients initially ventilated with NIV than in the other 
groups (SOT: 18%, HFNC: 20%, NIV: 37%, IMV: 25%) 
(Fig. 2b). In patients who did not progress toward intuba-
tion, the ICU mortality rates were as follows: 10% in the 
SOT, 7% in the HFNC, and 36% in the NIV group (Addi-
tional file 1: e-Table 4). The amount of therapy withdraw-
als was similar between groups (p = 0.408).
Characteristics of patients progressing toward intubation 
and invasive mechanical ventilation
The median duration of the in-hospital stay until intuba-
tion was longer (p<0.001) in the NIV group (4 [IQR, 3–7] 
days) compared to the other three groups (SOT: 3 [1–5] 
days, HFNC: 3 [2–6] days, IMV: 1 [0–3] days) (Table 2). 
At the day of intubation, patients progressing toward 
mechanical ventilation had an overall median partial 
pressure of arterial oxygen to inspired fraction of oxygen 
(P/F) ratio of 137 [95–179] mmHg, with no variations 
between groups (p =  0.256) (Table  2). In all groups the 
Patients included in the registry, N= 1421
Patients meeting inclusion criteria, N= 877
  • Standard oxygen therapy ≥10 L/min, N= 85
  • High-Flow oxygen therapy, N= 87
  • Non-invasive ventilation, N= 87
  • Invasive mechanical ventilation, N= 618
Patients included in final analysis, N= 351
Patients excluded, N= 544
 • Standard oxygen therapy < 10 L/min at day 1, N= 328
 • Missing outcome, N= 216
Patients with invasive mechanical ventilation excluded 
after matching, N= 526
Patients under invasive mechanical ventilation
N= 92
Patients under Standard Oxygen Therapy
N = 85
Patients under High-Flow Oxygen Therapy
N = 87
Patients under Non-Inasive Ventilation
N = 87
Intubated
N = 45
(52%)
Not Intubated
N = 42
Alive
N = 39
Dead
N = 3
(7%)
Alive
N = 31
Dead
N = 14
(31%)
Intubated
N = 54
(64%)
Not Intubated
N = 31
Alive
N = 28
Dead
N = 3
(10%)
Alive
N = 42
Dead
N = 12
(22%)
Intubated
N = 43
(49%)
Not Intubated
N = 44
Alive
N = 28
Dead
N = 16
(36%)
Alive
N = 27
Dead
N = 16
(37%)
Alive
N = 69
Dead
N = 23
(25%)
Fig. 1 Study flowchart
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initial ventilator settings and static compliance were simi-
lar. The use of corticosteroids and prone positioning were 
also comparable between groups. Patients under early 
IMV experienced less pronounced C-reactive protein 
(CRP) dynamics, with a lower proportional peak increase 
and a larger proportional decrease over the initial 7 days 
of ICU stay compared to patients in the noninvasive res-
piratory support groups (p  =  0.02) (Additional file  1: 
e-Figure  4; Additional file  1:  e-Table  5). Patients who 
received initial NIV therapy had a greater need for vaso-
pressors during the ICU stay (p = 0.029).
Table 1 Demographics, characteristics at ICU admission, progression of respiratory support and outcome
Values are given as median [interquartile range] or count (percent) as appropriate
ICU intensive care unit, APACHE II Acute Physiology And Chronic Health Evaluation II, SAPS II Simplified Acute Physiology Score II, SOFA Sequential Organ Failure 
Assessment, FiO2 Fraction Of Inspired  O2, SpO2 Peripheral Oxygen Saturation, PaO2/FiO2 ratio Partial Pressure of Arterial  O2/Fraction Of Inspired  O2, CRP C-reactive 
protein
† Immunosuppression was defined as any of the following: Hematologic malignancy, Human Immunodeficiency Virus, Hepatitis B or C infection, prescribed 
immunosuppressive medication
Overall N = 351 Standard 
oxygen therapy 
N = 85
High-flow 
oxygen therapy 
N = 87
Non-invasive positive-
pressure ventilation 
N = 87
Invasive 
mechanical 
ventilation N = 92
P value
Centers that employed each 
strategy
49 (100) 28 (57) 21 (43) 26 (53) 35 (71)
Patient characteristics
Age, years 63 [55, 72] 63 [53, 72] 63 [55, 74] 66 [55, 76] 62 [55, 70] 0.454
Male gender 254 (73) 63 (75) 65 (75) 62 (71) 64 (71) 0.861
Body mass index, kg/m2 28 [25, 31] 28 [26, 32] 27 [25, 32] 26 [24, 29] 29 [26, 31] 0.029
Comorbidities 167 (47) 49 (57) 40 (46) 39 (44) 39 (42) 0.187
Ischemic heart disease 35 (10) 11 (12) 7 (8) 10 (11) 7 (7) 0.574
Diabetes mellitus 90 (25) 23 (27) 26 (29) 17 (19) 24 (26) 0.454
Chronic arterial hypertension 153 (43) 42 (49) 34 (39) 36 (41) 41 (44) 0.552
COPD 41 (11) 14 (16) 10 (11) 7 (8) 10 (10) 0.382
Immunosuppression† 40 (11) 7 (8) 13 (14) 7 (8) 13 (14) 0.311
On ICU admission
Time from symptom onset to 
hospitalization, days
7 [4, 10] 7 [4, 10] 7 [3, 10] 6 [3, 10] 7 [4, 9] 0.797
Time from hospital admission 
to ICU, days
1 [0, 3] 1 [0, 3] 1 [0, 3] 2 [1, 4] 1 [0, 3] 0.233
APACHE score 11 [7, 18] 11 [7, 19] 10 [6, 13] 10 [7, 16] 11 [8, 20] 0.045
SAPS II score 38 [30, 59] 37 [30, 63] 35 [27, 44] 36 [29, 57] 45 [35, 63] <0.001
SOFA score 7 [5, 8] 7 [4, 7] 6 [3, 7] 6 [4, 7] 7 [6, 8] 0.245
Vasopressors 32 (16) 9 (15) 5 (12) 11 (25) 7 (14) 0.341
Lactate, mmol/L 1.3 [0.9, 1.8] 1.1 [0.9, 1.5] 1.3 [0.9, 2] 1.5 [1, 1.8] 1.2 [0.9, 1.8] 0.352
FiO2, % 60 [50, 70] 60 [60, 60] 60 [44, 80] 60 [48, 70] 63 [45, 80] 0.180
Respiratory rate, 1/min 26 [22, 32] 28 [24, 32] 26 [22, 32] 28 [24, 37] 24 [21, 30] 0.052
SpO2, % 94 [91, 97] 92 [90, 94] 95 [92, 97] 94 [91, 97] 95 [92, 97] 0.118
PaO2/FiO2, mmHg 123 [92, 167] 117 [105, 160] 126 [79, 169] 135 [97, 168] 123 [90, 165] 0.612
CRP, mg/L 119 [33, 202] 153 [94, 217] 104 [31, 169] 111 [28, 202] 110 [23, 222] 0.052
Interleukin‑6, ng/L 115 [56, 210] 153 [41, 236] 105 [82, 150] 111 [70, 175] 94 [50, 325] 0.968
D‑dimer, µg/L 1146 [625, 2050] 1250 [653, 1899] 910 [505, 1628] 1394 [838, 5825] 1040 [638, 1905] 0.234
Outcome
Requirement of intubation 234 (67) 54 (64) 45 (52) 43 (49) 92 (100) <0.001
Withdrawal of life supporting 
therapies
51 (15) 14 (16) 8 (9) 15 (18) 14 (17) 0.408
ICU length of stay, days 13 [6, 23] 9 [3, 17] 13 [6, 24] 17 [8, 26] 15 [9, 24] <0.001
ICU mortality 87 (25) 15 (18) 17 (20) 32 (37) 23 (25) 0.016
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ICU mortality in patients requiring IMV was 28% (65) 
with a median length of stay of 16 [9–26] days. Patients 
initially treated with NIV who progressed toward IMV 
presented a trend (p =  0.073) toward higher ICU mor-
tality (37%) as opposed to patients in the other groups 
(SOT: 21%, HFNC: 31%) when compared to the early 
IMV group (25%) (Fig.  3a). Patients who were initially 
treated with HFNC and NIV, and later required IMV, 
had longer (p = 0.018) ICU lengths of stay than patients 
under initial SOT when compared to early IMV (Fig. 3b).
After multivariable adjustment for covariates, NIV 
was independently associated with a higher overall ICU 
mortality (adjusted HR 2.67, 95% CI [1.14–6.25]) as well 
as with an increased ICU mortality rate (adjusted HR 
2.96, 95% CI [1.07–8.23]) and a prolonged length of ICU 
stay (adjusted HR 0.57, 95% CI [0.33–0.97]) in patients 
failing NIV and requiring delayed IMV, as opposed to the 
other respiratory support strategies (Figs. 2b, 3a, b; Addi-
tional file 1: e-Figures 5–8).
Table 2 Characteristics and disease progression in patients requiring invasive mechanical ventilation
Values are given as median [IQR] or count (percent) as appropriate
ICU intensive care unit, SOFA Sequential Organ Failure Assessment, FiO2 fraction of inspired  O2, SpO2 peripheral oxygen saturation, PaO2/FiO2 ratio partial pressure of 
arterial  O2/fraction of inspired  O2, PaCO2 partial pressure of arterial  CO2, IBW ideal body weight, PEEP positive end expiratory pressure, CRP C-reactive protein
* Calculated by means of mixed effect model analysis (Additional file 1: e-Table 2)
Overall N = 234 Standard 
oxygen therapy 
N = 54
High-flow 
oxygen therapy 
N = 45
Non-invasive positive-
pressure ventilation 
N = 43
Invasive 
mechanical 
ventilation N = 92
P value
Time from hospital admission 
to intubation, days
2 [1, 5] 3 [1, 5] 3 [2, 6] 4 [3, 7] 1 [0, 3] <0.001
Duration of noninvasive 
respiratory support, days
1 [1, 2] 1 [1, 1] 1 [1, 2] 1 [1, 2] 0 [0, 0] 0.109
SOFA score on intubation day 6 [5, 8] 6 [6, 8] 7 [6, 8] 6 [5, 7] 7 [6, 8] 0.258
Ventilatory parameters after intubation
FiO2, % 60 [44, 75] 50 [40, 67] 60 [44, 67] 45 [41, 65] 63 [45, 80] 0.022
SpO2, % 94 [90, 97] 91 [88, 95] 94 [91, 96] 93 [89, 96] 96 [92, 97] 0.082
PaO2/FiO2, mmHg 137 [95, 179] 143 [94, 195] 136 [99, 181] 146 [108, 169] 123 [90, 165] 0.256
PaCO2, kPa 5.5 [4.7, 6.4] 5.8 [5.1, 6.7] 5.8 [4.7, 6.6] 5.7 [4.9, 6.4] 5.1 [4.3, 5.8] 0.002
Tidal volume/IBW, ml/kg 6.0 [5.6 , 7] 6.4 [5.7, 7.0] 6.0 [5.5, 6.7] 6.0 [5.6, 7.3] 6.1 [5.7, 7.1] 0.982
Respiratory rate, 1/min 24 [20, 28] 24 [20, 28] 21 [18, 27] 23 [20. 27] 24 [21, 30] 0.008
PEEP,  cmH2O 12 [10, 12] 10 [10, 12] 10 [10, 12] 12 [10, 14] 12 [10, 14] 0.266
Plateau pressure,  cmH2O 23 [21, 26] 24 [22, 25] 24 [22, 25] 24 [23, 27] 21 [21, 25] 0.838
Driving pressure,  cmH2O 13 [10, 14] 13 [10, 14] 14 [12, 15] 13 [12, 14] 11 [10, 14] 0.96
Static compliance, ml/cmH2O 35 [26, 44] 34 [27, 44] 29 [25, 36] 28 [24, 34] 36 [31, 49] 0.603
Treatment
Corticosteroids 50 (21) 11 (20) 13 (29) 12 (28) 14 (15) 0.194
Organ failure and support during ICU stay
Prone positioning 148 (63) 35 (64) 31 (68) 27 (62) 55 (59) 0.764
Decrease in CRP from Day 
0–7, %
27 [−77, 83] 19 [−100, 67] 17 [−27, 90] 21 [−103, 85] 42 [−48, 87] 0.02*
Vasopressors 187 (80) 45 (83) 38 (84) 39 (91) 65 (71) 0.029
Acute kidney injury 52 (22) 9 (17) 16 (36) 11 (26) 16 (17) 0.068
Renal replacement therapy 40 (17) 9 (17) 9 (20) 6 (14) 16 (17) 0.901
Tracheotomy 41 (17) 7 (13) 11 (24) 7 (16) 16 (17) 0.346
Outcome
Withdrawal of life supporting 
therapies
38 (17) 11 (20) 6 (13) 7 (17) 14 (17) 0.857
ICU length of stay, days 16 [9, 26] 13 [7, 21] 21 [13, 29] 18 [9, 27] 15 [9, 24] 0.052
ICU mortality 65 (28) 12 (21) 14 (31) 16 (37) 23 (25) 0.342
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Predictors of mortality in patients initially treated 
with HFNC or NIV patients with delayed intubation 
and invasive mechanical ventilation
To identify the HFNC and NIV patients with the worst 
ICU outcomes after progression to intubation and IMV, 
an iterative, multivariable GLM analysis was performed. 
The model identified age, respiratory rate and diagnosis 
of diabetes mellitus as independent prognostic factors of 
mortality (Additional file  1: e-Table  6; Additional file  1: 
e-Figure 9A). A prognostic score, based on the previously 
described model, presented a moderate prognostic abil-
ity (area under the receiver operating curve: 0.75, 95% 
CI [0.63–0.85]) for ICU mortality in these patients. This 
prognostic score was superior to all other tested prog-
nostic scores at ICU admission (Additional file 1: e-Fig-
ure  9B; Additional file  1: e-Table  9). The Kaplan–Meier 
estimator presented in Additional file  1: e-Figure  9C 
shows the excellent (p<0.0001) dichotomizing capacity 
of a prognostic score of 134 points (Positive Likelihood 
Ratio for Mortality: 2.4) to identify patients with a higher 
risk of ICU mortality.
Discussion
In this subpopulation of a prospective, critically ill 
COVID-19 cohort during the first peak of the pandemic, 
70% of patients were intubated and mechanically ven-
tilated on the day of admission to the ICU. Use of SOT, 
HFNC and NIV was limited to 10% of the patients, 
respectively. The incidence of intubation and IMV in 
patients initially supported with HFNC and NIV was 
12–15% lower than in patients with SOT. Compared to 
the other respiratory support strategies, NIV was associ-
ated with higher ICU mortality rates. A prognostic score 
considering age, respiratory rate and diabetes mellitus 
at ICU admission performed moderately in identifying 
HFNC and NIV patients with increased mortalities after 
delayed intubation and may help to discern patients who 
are at lower risk for increased ICU mortality during a 
HFNC or NIV trial.
International guidelines in place at the onset of the pan-
demic recommended early IMV for critically ill COVID-
19 patients; HFNC and NIV were not recommended, 
mainly due to safety concerns related to the production 
of aerosols, which could jeopardize the health of hospital 
staff [23]. Notwithstanding those recommendations, the 
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Fig. 2 Kaplan–Meier curves for the a incidence of intubation and b intensive care unit mortality stratified by respiratory support strategy at 
intensive care unit admission. Forest plots reporting crude and multivariable adjusted (*italic) hazard ratios with 95% confidence intervals are 
displayed below the Kaplan–Meier curves for each respiratory support strategy. †p values for between groups survival curve difference were 
calculated by means of the log‑rank test
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proportion of patients ventilated with noninvasive res-
piratory support strategies in this study was comparable 
to that described in the setting of the LUNGSAFE study, 
in which 15% of patients received noninvasive respiratory 
support [24]. Numerous COVID-19 cohort studies con-
ducted in Europe and the United States have described 
similar proportions of noninvasive support measures [7, 
18, 25–27].
Although contradictory results have been reported 
regarding the value of HFNC to avoid intubation [20, 28], 
this technique has been shown to reduce mortality rates 
in cases of acute hypoxemic failure [20], thus finding its 
place in international respiratory support recommenda-
tions [29]. In critically ill COVID-19 patients, other stud-
ies have shown—consistent with the data presented in 
our study—lower intubation and IMV rates, but without 
any reduction in ICU mortality [30]. The initially postu-
lated risk of virus aerosolisation can probably be mini-
mized by using conventional type I surgical masks over 
the nasal cannula [31]. By contrast, NIV remains con-
troversial in the treatment of ARDS, a debate that is evi-
dent in the absence of unambiguous recommendations 
in clinical guidelines [32]. Although the use of NIV has 
been correlated with a reduced need for IMV and lower 
mortality rates in mild ARDS [33], the available evidence 
in severer expressions of ARDS indicates higher mortal-
ity rates [20, 24, 34]. In ARDS of viral etiology especially, 
the use of NIV is associated with high failure rates (up to 
85%) [35].
Patients may—in an attempt to maintain homeosta-
sis—initiate a vicious cycle through vigorous breathing 
efforts, exacerbating their lungs pathology by means of 
extremely elevated transpulmonary forces, leading to 
excessive stress and increased pulmonary inflammation 
[36, 37]. In our study, this patient-induced biotrauma 
might be one of the factors explaining the pronounced 
CRP dynamics in the noninvasively supported groups 
as opposed to those receiving early IMV [38]. Conse-
quently, the prolonged use of noninvasive ventilation, 
delaying intubation in patients who ultimate fail and thus 
require IMV, has been associated with higher mortality 
rates in ARDS [39–43], as well as in critically ill COVID-
19 patients [44–46]. The excess mortality observed in 
patients treated with NIV in this study might thus be 
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explained by the longer period of harmful spontaneous 
breathing in patients failing NIV therapy, exacerbated by 
an increased respiratory rate and disproportionate tidal 
volumes induced by NIV therapy [24, 47].
If faced with a choice, physicians will intuitively pri-
oritize avoidance of intubation and IMV, provided that 
this strategy does not imply any increase in mortality 
risk. Thus, the data presented in this study suggests that 
the best strategy appears to be an initial closely moni-
tored HFNC trial with thorough assessment of clinical 
improvement, followed by proactive intubation and IMV 
in patients with a high risk of failure and mortality. The 
use of prognostic scores, such as the one exemplified in 
this study, may support clinical decision making to dif-
ferentiate between patients who are treatable with non-
invasive respiratory support strategies from those likely 
to have a worse outcome if intubation is delayed [48, 49]. 
To which degree static scores or dynamic scores taking 
advantage of the temporal assessment of patients, such as 
the ROX score, may improve ICU outcome nevertheless 
remains to be assessed [18, 49].
The present study has several limitations. First, the lack 
of randomization between respiratory support groups 
and it being a retrospective analysis, lead to many pos-
sible outcome modifying biases, such as the inability to 
assess the influence of human and material resources on 
treatment outcomes. Nonetheless, the lack of randomi-
zation was minimized through the application of pro-
pensity score matching to numerous variables at ICU 
admission, thus ensuring the comparability of the study 
groups in terms of the most objectively assessable patient 
characteristics. Second, the lack of a universal respiratory 
support protocol implies a high level of center- and cli-
nician-related variability and prevents a mechanistic rea-
soning behind the described effects. On the other hand, 
the observational nature of this study potentially reflects 
the clinicians’ expertise more than a protocolized, rand-
omized four-arm study, thereby reducing bias caused by 
variations in clinical experience or disfavour of a specific 
type of respiratory support strategy. Consequently the 
present study offers a representative view of the respira-
tory support strategies employed during the first peak of 
the pandemic. Third, some of the crude mortality trends 
observed in this study lacked statistical significance. 
However, given the moderate numbers of patients in each 
ventilation strategy, the large number of centers, the lack 
of a centralized protocol, and the statistical significance 
in the adjusted analyses, the observed signals provide a 
certain robustness for clinical decision-making and the 
development of hypotheses for future confirmatory, con-
trolled studies. Fourth, the available registry data did 
not allow to determine the time on IMV for all patients, 
thus preventing an analysis of ventilator-free time. Fifth, 
the data underlying the prognostic score analysis were 
assessed on a daily basis, thus diminishing the prognostic 
capacity for scores, which require higher temporal reso-
lution. Finally, the here proposed prognostic score has 
not been validated in other NIV and HFNC populations, 
thus caution is advised when employing it in a clinical 
framework; external validation is warranted.
Conclusion
Given that patients who received HFNC in this cohort 
had lower intubation rates but comparable ICU mortality, 
the most reasonable initial ventilation strategy in criti-
cally ill COVID-19 patients appears to be a closely moni-
tored trial of HFNC, prioritizing rapid intubation and 
IMV in patients with a high risk of failure. Nonetheless, 
considering the highly uncertain and stressful clinical 
setting experienced during the first wave of the COVID-
19 pandemic, SOT and early IMV both represent safe 
and “cautious” initial respiratory support strategies. The 
presented findings, in agreement with classic ARDS lit-
erature, suggest that NIV should be avoided whenever 
possible due to an associated elevated ICU mortality risk.
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